At the 2025 BIO Asia–Taiwan, GeneOnline visited the China Medical University (CMU) pavilion to conduct in-depth interviews with outstanding teams in the fields of novel drug development and cell therapy:
🔸 Ever Supreme Bio Technology Co., Ltd. (6712.TWO)
Dr. Sammy Hsu, Senior Manager, shared the latest progress of the world’s only allogeneic CAR-T BiTE technology for solid tumors. Clinical data revealed a 72.89% tumor size reduction in a colorectal cancer case. The CAR001 therapy is now nearing the completion of FDA and TFDA-approved Phase I trials.
🔸 Shine Out Bio
Vice President Lee Ming-Juang introduced three patents and two core platforms focused on targeted exosome therapies for neurodegenerative diseases. Their d-EV platform received the 2024 National Innovation Award and is preparing for a pre-IND submission to the U.S. FDA.
🔸 Shine-On Biomedical
Quality Manager Ken Chang presented a globally first-of-its-kind trispecific antibody platform, combining Anti-HLA-G, Anti-PD-L1, and Anti-CD3 to activate T cells. The lead candidate, SOA101, is undergoing Phase I trials. Their exosome-based drug delivery technology is also entering early clinical development and holds strong licensing potential.
Which of these technologies made the biggest impression on you?
Share your thoughts in the comments!
